ContraFect
28 Wells Avenue, Third Floor
Yonkers, NY 10701
United States
Tel: 914-207-2300
Website: http://www.contrafect.com/
140 articles about ContraFect
-
ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/20/2022
ContraFect Corporation today announced that on May 16, 2022, the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock.
-
ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update
5/16/2022
ContraFect Corporation(Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the first quarter ended March 31, 2022.
-
ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone
4/27/2022
ContraFect Corporation announces presentation data showing DLA CF-370 is highly efficacious in a rabbit pneumonia model of a particularly hard-to-treat, extensively-drug-resistant strain of Pseudomonas aeruginosa, and also has the ability to both avoid antimicrobial resistance and suppress antibiotic resistance to commonly-used antibiotics in vitro.
-
ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting
4/18/2022
ContraFect Corporation announces today that the Company has been selected for an oral presentation and six poster presentations at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting to be held from April 23-26, 2022 in Lisbon, Portugal.
-
ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update
3/24/2022
ContraFect Corporation, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces business updates and financial results for the fourth quarter and full year ended December 31, 2021.
-
ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference
3/21/2022
ContraFect Corporation announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference, which is being held virtually from March 28–30, 2022.
-
ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference
2/10/2022
ContraFect Corporation announces that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference, which is being held virtually from February 14–18, 2022.
-
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis
1/6/2022
ContraFect Corporation, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces that it has received an additional award from the Cystic Fibrosis Foundation.
-
Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases
12/20/2021
ContraFect Corporation announces the recent publication of a case study report highlighting the potential of its first investigational direct lytic agent, exebacase, to treat methicillin-resistant Staphylococcus aureus bacteremia in a pediatric population.
-
ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/15/2021
ContraFect Corporation, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced financial results and business updates for the third quarter ended September 30, 2021.
-
ContraFect’s New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis
11/9/2021
ContraFect Corporation announces that data from the Company’s DLA programs, including lysin CF-370 and amurin peptide AM1, demonstrate the potential for their development as treatments for pulmonary infections associated with cystic fibrosis.
-
ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients
10/26/2021
ContraFect Corporation today announces it will be presenting a poster on the activity of DLAs against common Gram-negative pathogens responsible for pulmonary infections in Cystic Fibrosis patients at the North American Cystic Fibrosis Conference, which will be held virtually from November 2-5, 2021.
-
ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021
9/29/2021
ContraFect Corporation announces today that the Company has been selected to deliver a Late Breaker oral presentation on the rapid symptom resolution in adult patients with Staphylococcus aureus (Staph aureus) bacteremia who were treated with exebacase in the completed Phase 2 study.
-
ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference
9/22/2021
ContraFect Corporation announces that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Cantor Global Virtual Healthcare Conference, which is being held from September 27 – 30, 2021.
-
ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update
8/13/2021
ContraFect Corporation, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced financial results and business updates for the second quarter ended June 30, 2021.
-
ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity
7/19/2021
ContraFect Corporation announced the publication of two manuscripts that demonstrate the potent in vivo activity of CF-296, a novel engineered lysin agent with potent bactericidal and anti-biofilm activity against Staphylococcus aureus, a life-threatening pathogen.
-
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum
6/17/2021
ContraFect Corporation announced multiple presentations, including two oral presentations, of data from its portfolio of DLAs at the 2021 World Microbe Forum, being held virtually from June 20-24, 2021.
-
ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development
6/17/2021
ContraFect Corporation, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced that Gary Woodnutt, Ph.D. has been appointed as Senior Vice President of Translational Sciences and Preclinical Development.
-
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections
5/26/2021
Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function The observed clinical responses in patients treated under compassionate use in France warrant further study of the use of intra-articular administration of exebacase for prosthetic joint infection (PJI)
-
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
5/3/2021
ContraFect Corporation, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced that the United States Patent and Trademark Office issued U.S. Patent No. 10,988,520, on April 27, 2021 for CF-370, the company’s second potential therapeutic product candidate.